| Drug General Information |
| Drug ID |
D0Y8UV
|
| Former ID |
DND000015
|
| Drug Name |
EMD-1204831
|
| Indication |
Solid tumour/cancer
[ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229]
|
Phase 1 |
[1] |
| Company |
Merck KGaA
|
| Target and Pathway |
| Target(s) |
Proto-oncogene c-Met (MET) |
Target Info
|
Inhibitor |
[2] |
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Adherens junction
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Malaria
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Renal cell carcinoma
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Pathway Interaction Database
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
Syndecan-1-mediated signaling events
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
FGF signaling pathway
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Sema4D mediated inhibition of cell attachment and migration
|
|
WikiPathways
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Focal Adhesion
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Signaling Pathways in Glioblastoma
|
|
miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Semaphorin interactions
|
| References |
| REF 1 |
ClinicalTrials.gov (NCT01110083) First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
|
| REF 2 |
2012 ASCO Annual Meeting.
|
